Outcomes and Guidelines for MRI in Patients With DCIS
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.
Clinical Pearls I
- Outcome data should support the use of any expensive test
- Data does not exist to support the routine use of MRI in DCIS patients and invasive breast cancer patients
Clinical Pearls II
- It would be beneficial to have guidelines for the appropriate use of MRI
- Currently, the use of MRI is largely dependent on the surgeon and institution
Patritumab Deruxtecan With/Without Letrozole Shows Comparable Efficacy in HR+/HER2- Breast Cancer
December 11th 2024In the phase 2 SOLTI VALENTINE trial, patritumab deruxtecan with or without letrozole showed similar efficacy to multiagent chemotherapy in HR-positive, HER2-negative breast cancer with fewer severe adverse events.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
